Mihriban Tuna

USPTO Granted Patents = 14 (Patent Applications = 13)

EPO Patents = 12 (Patent Applications = 24)

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 44(Granted Patents)

Company Filing History:

F-star Therapeutics, Inc.

patents

1 out of 4,179

Abbott Laboratories Corporation

Gammadelta Therapeutics Ltd

patents

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12344672 - Antibody molecules that bind PD-L1 and CD137 (2025-07-01),

2. 12325742 - Anti-mesothelin antibodies (2025-06-10),

3. 12319739 - Mesothelin and CD137 binding molecules (2025-06-03),

4. 12312408 - Multispecific anti-TCR delta variable 1 antibodies (2025-05-27),

5. 12297283 - Fc binding fragments comprising an OX40 antigen-binding site (2025-05-13),

6. 12252537 - Antibody molecules that bind CD137 and OX40 (2025-03-18),

7. 12187798 - LAG-3 binding members (2025-01-07),

8. 12103976 - Fc binding fragments comprising a CD137 antigen-binding site (2024-10-01),

9. 11629193 - EGFR binding molecules (2023-04-18),

10. 11629189 - Bispecific antibody for ICOS and PD-L1 (2023-04-18),

11. 11548948 - FC binding fragments comprising a PD-L1 antigen-binding site (2023-01-10),

12. 11214620 - Binding molecules binding PD-L1 and LAG-3 (2022-01-04),

13. 11214618 - LAG-3 binding members (2022-01-04),

14. 8324350 - Dual-specific IL-1α/IL-1β antibodies (2012-12-04),

Title: The Innovative Contributions of Mihriban Tuna

Introduction

Mihriban Tuna, an accomplished inventor based in Cambridge, GB, has made significant strides in the field of biotechnology and pharmaceuticals, with a remarkable portfolio of 14 patents. His innovative work focuses on developing antibody molecules with the potential to revolutionize cancer treatment.

Latest Patents

One of Mihriban Tuna's latest inventions includes antibody molecules that bind both PD-L1 and CD137. This application relates to antibody molecules designed to trigger agonism of CD137, utilizing a CDR-based binding site for PD-L1. These innovative antibody molecules are envisioned for use in treating various diseases, particularly cancer. Additionally, he has patented anti-mesothelin antibodies that target mesothelin (MSLN), which also hold substantial promise for diagnosing and treating cancer-related disorders.

Career Highlights

Mihriban Tuna has had an impressive professional trajectory, having worked with prominent companies such as Invox Pharma Limited and F-Star Therapeutics, Inc. His endeavors in these organizations demonstrate his commitment to advancing biopharmaceutical solutions through innovation and research.

Collaborations

Throughout his career, Mihriban has collaborated with distinguished colleagues, including Francisca Wollerton Van Horck and Miguel Gaspar. These partnerships have undoubtedly fostered an environment of innovation, enabling groundbreaking research and development in the field of antibodies and cancer treatment.

Conclusion

With a robust portfolio of patents and a strong foundation in biopharmaceutical research, Mihriban Tuna continues to impact the medical world significantly. His dedication to developing innovative antibody therapies positions him as a leading inventor in combating cancer and enhancing diagnostic techniques. The contributions of inventors like Mihriban Tuna pave the way for improved health solutions and transformative medical practices.

This text is generated by artificial intelligence and may not be accurate.